CONMED (CNMD)
(Delayed Data from NYSE)
$76.25 USD
+0.75 (0.99%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $76.30 +0.05 (0.07%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth D Momentum B VGM
Income Statements
Fiscal Year end for CONMED Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,245 | 1,045 | 1,011 | 862 | 955 |
Cost Of Goods | 569 | 474 | 443 | 402 | 430 |
Gross Profit | 676 | 571 | 568 | 460 | 525 |
Selling & Adminstrative & Depr. & Amort Expenses | 556 | 501 | 458 | 414 | 446 |
Income After Depreciation & Amortization | 121 | 70 | 110 | 46 | 79 |
Non-Operating Income | 0 | -112 | -1 | 0 | -5 |
Interest Expense | 40 | 29 | 35 | 44 | 43 |
Pretax Income | 81 | -71 | 73 | 2 | 31 |
Income Taxes | 16 | 10 | 11 | -8 | 3 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 64 | -81 | 63 | 10 | 29 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 64 | -81 | 63 | 10 | 29 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 199 | 144 | 194 | 132 | 163 |
Depreciation & Amortization (Cash Flow) | 78 | 74 | 85 | 86 | 84 |
Income After Depreciation & Amortization | 121 | 70 | 110 | 46 | 79 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 31.55 | 30.04 | 32.22 | 29.46 | 29.50 |
Diluted EPS Before Non-Recurring Items | 3.45 | 2.65 | 3.21 | 2.18 | 2.64 |
Diluted Net EPS (GAAP) | 2.04 | -2.68 | 1.94 | 0.32 | 0.97 |
Fiscal Year end for CONMED Corporation falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 332.10 | 312.27 | 327.05 | 304.58 | 317.65 |
Cost Of Goods | 148.37 | 140.31 | 144.87 | 136.52 | 146.96 |
Gross Profit | 183.73 | 171.97 | 182.18 | 168.06 | 170.69 |
SG&A, R&D, and Dept/Amort Expenses | 136.62 | 136.95 | 131.99 | 137.76 | 143.27 |
Income After SG&A, R&D, and Dept/Amort Expenses | 47.11 | 35.02 | 50.19 | 30.30 | 27.42 |
Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 9.59 | 9.59 | 9.50 | 10.02 | 10.00 |
Pretax Income | 37.51 | 25.42 | 40.68 | 20.28 | 17.42 |
Income Taxes | 7.54 | 5.71 | 7.61 | 4.44 | 3.69 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 29.98 | 19.71 | 33.07 | 15.84 | 13.73 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 29.98 | 19.71 | 33.07 | 15.84 | 13.73 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 31.11 | 31.27 | 31.50 | 31.69 | 31.80 |
Diluted EPS Before Non-Recurring Items | 0.98 | 0.79 | 1.06 | 0.90 | 0.83 |
Diluted Net EPS (GAAP) | 0.96 | 0.63 | 1.05 | 0.50 | 0.43 |